AEMD Overview

Aethlon Medical, Inc. is a clinical-stage medical device company. The Company is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.

Wall Street analysts forecast AEMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AEMD is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aethlon Medical Inc revenue for the last quarter amounts to 0.00 USD, decreased

Aethlon Medical Inc. EPS for the last quarter amounts to -2.45 USD, decreased -75.62

Aethlon Medical Inc (AEMD) has 9 emplpoyees as of April 21 2026.

Today AEMD has the market capitalization of 3.75M USD.